Mark Selby
Overview
Explore the profile of Mark Selby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
3430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rice-Boucher P, Mendonca S, Alvarez A, Sturtz A, Lorincz R, Dmitriev I, et al.
Mol Ther
. 2023 Jul;
31(9):2600-2611.
PMID: 37452494
B cells are the antibody-producing arm of the adaptive immune system and play a critical role in controlling pathogens. Several groups have now demonstrated the feasibility of using engineered B...
2.
Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W, et al.
J Clin Oncol
. 2023 Jan;
41(4):715-723.
PMID: 36706735
Purpose: Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade...
3.
Thudium K, Selby M, Zorn J, Rak G, Wang X, Bunch R, et al.
Cancer Immunol Res
. 2022 Aug;
10(10):1175-1189.
PMID: 35981087
Novel therapeutic approaches combining immune-checkpoint inhibitors are needed to improve clinical outcomes for patients with cancer. Lymphocyte-activation gene 3 (LAG-3) is an immune-checkpoint molecule that inhibits T-cell activity and antitumor...
4.
Williams N, Seymour I, Leah R, Mukerjee S, Selby M, Skinner S
Phys Chem Chem Phys
. 2021 May;
23(27):14569-14579.
PMID: 33988196
The local activation overpotential describes the electrostatic potential shift away from equilibrium at an electrode/electrolyte interface. This electrostatic potential is not entirely satisfactory for describing the reaction kinetics of a...
5.
Campbell J, McDonald B, Mesko P, Siemers N, Singh P, Selby M, et al.
Cancer Res
. 2021 Mar;
81(11):2983-2994.
PMID: 33757978
FOXP3 regulatory T cells (Treg) play a critical role in mediating tolerance to self-antigens and can repress antitumor immunity through multiple mechanisms. Therefore, targeted depletion of tumor-resident Tregs is warranted...
6.
Renner K, Bruss C, Schnell A, Koehl G, Becker H, Fante M, et al.
Cell Rep
. 2019 Oct;
29(1):135-150.e9.
PMID: 31577944
Tumor-derived lactic acid inhibits T and natural killer (NK) cell function and, thereby, tumor immunosurveillance. Here, we report that melanoma patients with high expression of glycolysis-related genes show a worse...
7.
Harris-Bookman S, Mathios D, Martin A, Xia Y, Kim E, Xu H, et al.
Int J Cancer
. 2018 Sep;
143(12):3201-3208.
PMID: 30248181
Like in many tumor types, immunotherapy is currently under investigation to assess its potential efficacy in glioblastoma patients. Trials are under way to assess the efficacy of new immune checkpoint...
8.
Hung A, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik A, et al.
Oncoimmunology
. 2018 Sep;
7(8):e1466769.
PMID: 30221069
The use of inhibitory checkpoint blockade in the management of glioblastoma has been studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently discovered to play...
9.
Dahan R, Sega E, Engelhardt J, Selby M, Korman A, Ravetch J
Cancer Cell
. 2017 Aug;
28(4):543.
PMID: 28854351
No abstract available.
10.
Patel M, Kim J, Theodros D, Tam A, Velarde E, Kochel C, et al.
J Immunother Cancer
. 2016 Nov;
4:74.
PMID: 27822377
[This corrects the article DOI: 10.1186/s40425-016-0132-2.].